BRPI0410933A - novos antagonistas do receptor p2x7 e seu uso - Google Patents

novos antagonistas do receptor p2x7 e seu uso

Info

Publication number
BRPI0410933A
BRPI0410933A BRPI0410933-3A BRPI0410933A BRPI0410933A BR PI0410933 A BRPI0410933 A BR PI0410933A BR PI0410933 A BRPI0410933 A BR PI0410933A BR PI0410933 A BRPI0410933 A BR PI0410933A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
therapy
processes
formula
preparation
Prior art date
Application number
BRPI0410933-3A
Other languages
English (en)
Inventor
Richard Evans
Christine Eyssade
Rhonan Ford
Barrie Martin
Toby Thompson
Paul Willis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38812906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410933(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0410933A publication Critical patent/BRPI0410933A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"NOVOS ANTAGONISTAS DO RECEPTOR P2X~ 7~ E SEU USO". A invenção provê compostos de fórmula (IA), a processos para sua preparação, a composições farmacêuticas os contendo, e a seu uso em terapia.
BRPI0410933-3A 2003-06-02 2004-06-01 novos antagonistas do receptor p2x7 e seu uso BRPI0410933A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0312609.1A GB0312609D0 (en) 2003-06-02 2003-06-02 Novel compounds
SE0301700A SE0301700D0 (sv) 2003-06-02 2003-06-10 Novel compounds
PCT/SE2004/000836 WO2004106305A1 (en) 2003-06-02 2004-06-01 New p2x7 receptor antagonists and their use

Publications (1)

Publication Number Publication Date
BRPI0410933A true BRPI0410933A (pt) 2006-06-27

Family

ID=38812906

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410933-3A BRPI0410933A (pt) 2003-06-02 2004-06-01 novos antagonistas do receptor p2x7 e seu uso

Country Status (26)

Country Link
US (2) US7408065B2 (pt)
EP (1) EP1633717B1 (pt)
JP (1) JP4682128B2 (pt)
KR (1) KR101244971B1 (pt)
CN (1) CN1832925B (pt)
AR (1) AR045691A1 (pt)
AT (1) ATE446953T1 (pt)
AU (1) AU2004242626B2 (pt)
BR (1) BRPI0410933A (pt)
CA (1) CA2526884C (pt)
CO (1) CO5700720A2 (pt)
DE (1) DE602004023840D1 (pt)
ES (1) ES2333721T3 (pt)
GB (1) GB0312609D0 (pt)
HK (1) HK1085736A1 (pt)
IS (1) IS8190A (pt)
MX (1) MXPA05012883A (pt)
NO (1) NO20060001L (pt)
RU (1) RU2347778C2 (pt)
SA (1) SA04250155B1 (pt)
SE (1) SE0301700D0 (pt)
TW (1) TW200508214A (pt)
UA (1) UA83659C2 (pt)
UY (1) UY28342A1 (pt)
WO (1) WO2004106305A1 (pt)
ZA (1) ZA200509706B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
WO2005035551A2 (en) 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
JP2008513426A (ja) * 2004-09-20 2008-05-01 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
AU2006204159A1 (en) * 2005-01-06 2006-07-13 Astrazeneca Ab Novel pyridine compounds
US7402596B2 (en) * 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US20080312208A1 (en) * 2005-07-13 2008-12-18 Astrazeneca Ab Pyridine Analogues
EP1919485A4 (en) * 2005-08-01 2011-03-23 Phenomix Corp METHOD FOR PRODUCING HETEROCYCLIC BORONIC ACIDS AND ITS DERIVATIVES
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EP1943234A1 (en) * 2005-10-31 2008-07-16 Biolipox AB Triazole compounds as lipoxygenase inhibitors
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
US20090088463A1 (en) * 2005-11-01 2009-04-02 Benjamin Pelcman Pyrazoles Useful in the Treatment of Inflammation
US8007849B2 (en) * 2005-12-14 2011-08-30 International Flavors & Fragrances Inc. Unsaturated cyclic and acyclic carbamates exhibiting taste and flavor enhancement effect in flavor compositions
US8546579B2 (en) 2006-03-16 2013-10-01 Evotec (Us) Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
JP5306986B2 (ja) * 2006-03-16 2013-10-02 エボテック （ユーエス） インコーポレイテッド Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用
EP1996585A4 (en) * 2006-03-16 2010-03-10 Renovis Inc BICYCLOHETEROARYL COMPOUNDS AS PX27 MODULATORS AND ITS USES
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
US20080058309A1 (en) * 2006-07-27 2008-03-06 Astrazeneca Ab Novel Compounds 171
JP5111509B2 (ja) * 2006-09-28 2013-01-09 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ結合性を有するキノリン誘導体
JP2010510987A (ja) 2006-11-27 2010-04-08 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド誘導体
CA2669590A1 (en) 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag 2-aminoquinolines as 5-ht(5a) receptor antagonists
WO2008114002A1 (en) * 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
BRPI0809567A2 (pt) * 2007-04-10 2014-09-23 Lundbeck & Co As H Composto, composição farmacêutica, método para modular a atividade de um receptor de p2x7, para tratar uma condição responsiva à modulação do receptor de p2x7 em um paciente, para inibir a morte de células do gânglio retinal em um paciente, e para determinar a presença ou ausência do receptor de p2x7 em uma amostra, preparação farmacêutica acondiciaonada, e, uso de um composto
PE20091036A1 (es) * 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
CN101959864A (zh) 2008-03-07 2011-01-26 弗·哈夫曼-拉罗切有限公司 2-氨基喹啉衍生物
ATE494926T1 (de) 2008-03-25 2011-01-15 Affectis Pharmaceuticals Ag Neuartige p2x7r-antagonisten und ihre verwendung
KR101598397B1 (ko) * 2008-04-22 2016-02-29 얀센 파마슈티카 엔.브이. 퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
MX2011010810A (es) 2009-04-14 2012-01-12 Affectis Pharmaceuticals Ag Nuevos antagonistas de p2x7r y su uso.
JP5685203B2 (ja) * 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
EP2386541A1 (en) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2574840T3 (es) 2011-07-22 2016-06-22 Actelion Pharmaceuticals Ltd. Derivados de amidas heterocíclicas como antagonistas de receptores p2x7
PL2804865T3 (pl) 2012-01-20 2016-06-30 Idorsia Pharmaceuticals Ltd Heterocykliczne pochodne amidowe jako antagoniści receptora p2x7
CN104812749B (zh) 2012-12-12 2016-12-14 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
JP6295270B2 (ja) 2012-12-18 2018-03-14 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしてのインドールカルボキサミド誘導体
CA2897459C (en) 2013-01-22 2021-03-02 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
JP6282016B2 (ja) 2013-01-22 2018-02-21 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
EP2970271B1 (en) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7 modulators
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
WO2015187905A1 (en) * 2014-06-05 2015-12-10 Merck Patent Gmbh Novel quinoline derivatives and their use in neurodegenerative diseases
ES2714048T3 (es) 2014-09-12 2019-05-24 Janssen Pharmaceutica Nv Moduladores de P2X7
CN106084068B (zh) * 2016-06-16 2019-07-16 郑州大学第一附属医院 一组肠菌素-抗生素衍生物及其应用
EP3609868B1 (en) * 2017-03-13 2023-10-18 RaQualia Pharma Inc. Tetrahydroquinoline derivatives as p2x7 receptor antagonists
EP3398941A1 (en) 2017-05-03 2018-11-07 AXXAM S.p.A. Heterocyclic p2x7 antagonists
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
EP3856179A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica N.V. Monoacylglycerol lipase modulators
US11839663B2 (en) 2019-09-30 2023-12-12 Janssen Pharmaceutica Nv Radiolabelled MGL pet ligands
JP2023518511A (ja) 2020-03-26 2023-05-01 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ調節因子

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
US3741491A (en) * 1971-11-29 1973-06-26 Leesona Corp Apparatus for winding yarn
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
ES2099206T3 (es) 1991-02-21 1997-05-16 Sankyo Co Derivados de benceno que favorecen la produccion del factor de crecimiento de los nervios humanos.
HU222178B1 (hu) 1993-08-10 2003-04-28 James Black Foundation Ltd. Gasztrin és CCK-receptor ligandumok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények
PL186665B1 (pl) 1994-05-27 2004-02-27 Smithkline Beecham Spa Pochodne chinoliny jako antagoniści receptorów NKtachykininy, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca pochodne chinoliny oraz ich zastosowanie
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
SK283162B6 (sk) * 1996-05-20 2003-03-04 Darwin Discovery Limited Karboxamid chinolínu ako inhibítor faktora nekrotizujúceho nádor, inhibítor fosfodiesterázy-IV a farmaceutický prostriedok s jeho obsahom
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1999026927A2 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
RU2254333C2 (ru) 1999-04-09 2005-06-20 Астразенека Аб Производные адамантана, способ их получения, фармацевтическая композиция на их основе и способы лечения
WO2000073283A1 (en) 1999-06-02 2000-12-07 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
MXPA02004985A (es) * 1999-11-26 2003-10-14 Shionogi & Co Antagonistas del neuropeptido y, y5.
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
ES2260458T3 (es) * 2001-07-02 2006-11-01 Akzo Nobel N.V. Derivados de tetrahidroquinolina.
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
WO2003045313A2 (en) 2001-11-27 2003-06-05 Merck & Co. Inc. 2-aminoquinoline compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0402925D0 (sv) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
EP1633717B1 (en) 2009-10-28
GB0312609D0 (en) 2003-07-09
RU2005136130A (ru) 2006-06-27
ATE446953T1 (de) 2009-11-15
WO2004106305A1 (en) 2004-12-09
SA04250155B1 (ar) 2008-11-15
SE0301700D0 (sv) 2003-06-10
CO5700720A2 (es) 2006-11-30
UA83659C2 (ru) 2008-08-11
UY28342A1 (es) 2004-12-31
AR045691A1 (es) 2005-11-09
DE602004023840D1 (de) 2009-12-10
EP1633717A1 (en) 2006-03-15
ZA200509706B (en) 2006-12-27
CA2526884C (en) 2012-10-16
MXPA05012883A (es) 2006-02-22
US20090143354A1 (en) 2009-06-04
HK1085736A1 (en) 2006-09-01
JP2006526617A (ja) 2006-11-24
CN1832925B (zh) 2010-05-05
US7408065B2 (en) 2008-08-05
KR101244971B1 (ko) 2013-03-18
NO20060001L (no) 2006-03-02
TW200508214A (en) 2005-03-01
AU2004242626A1 (en) 2004-12-09
JP4682128B2 (ja) 2011-05-11
CN1832925A (zh) 2006-09-13
IS8190A (is) 2005-12-21
ES2333721T3 (es) 2010-02-26
KR20060015741A (ko) 2006-02-20
CA2526884A1 (en) 2004-12-09
RU2347778C2 (ru) 2009-02-27
AU2004242626B2 (en) 2008-03-13
US20060293337A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
BRPI0410933A (pt) novos antagonistas do receptor p2x7 e seu uso
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
EE200300524A (et) Ühendid, mis on CB2-retseptori agonistid, neid sisaldavad ravimkoostised ja nimetatud ühendite kasutamine ravis
BR0111667A (pt) Novos compostos
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
MY137535A (en) New pyrrolidinium derivatives
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
BR0108678A (pt) Novos compostos
BR0114754A (pt) Compostos não-imidazóis
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
UY28348A1 (es) Compuestos novedosos
MY131890A (en) Piperidine compounds
CL2004000889A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
PT1506185E (pt) Compostos novos e sua utilizacao
ATE231872T1 (de) Thiazolopyrimidinderivate
BRPI0512986A (pt) novos derivados de hidantoìna
BR0314844A (pt) Novo composto
BR0314843A (pt) Novo composto
BR0111669A (pt) Novos compostos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2310 DE 14-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.